Navigation Links
Newer Drug Beats Tamoxifen for Older Breast Cancer Patients
Date:8/19/2009

Letrozole boosted survival and should be first-line treatment, experts say

WEDNESDAY, Aug. 19 (HealthDay News) -- For postmenopausal women with breast cancer, treatment with the drug letrozole (Femara) increases survival after surgery more than the widely used tamoxifen, a new study confirms.

Both letrozole and tamoxifen have been used to prevent recurrence of breast cancer in postmenopausal women with hormone receptor-positive cancer, but whether one drug is better than the other has been unclear. The new study compared the impact of the newer drug, letrozole, to tamoxifen.

"This study reinforces the benefits of letrozole over tamoxifen, and leaves five years upfront use [of letrozole] as the preferred option, especially in patients judged to be at higher risk for recurrence," said lead researcher Dr. Alan Coates, co-chair of the scientific committee of the International Breast Cancer Study Group and a clinical professor in the School of Public Health at the University of Sydney, Australia.

The report is published in the Aug. 20 issue of the New England Journal of Medicine.

For the study, Coates and colleagues randomly assigned more than 8,000 postmenopausal women with hormone receptor-positive breast cancer to treatment with tamoxifen or letrozole for five years. In addition, some of the women were assigned to switch medicines after two years.

The study shows strong, though not incontrovertible, evidence that letrozole prolongs overall survival in comparison to tamoxifen, and that "this would in all probability have been conventionally significant had the switch of therapy not occurred," Coates said.

The other question in the study was whether the letrozole should be given before or after a period of tamoxifen therapy, Coates said.

"Neither sequence was superior to five years of straight letrozole," he said. "We found that the differences were small, but that consistently in the higher risk subgroups there was a benefit to starting with letrozole."

The study also included starting with letrozole and switching to tamoxifen, Coates noted.

"The difference between straight letrozole and the reverse sequence was very small in all groups, which will be reassuring to those women who, having started adjuvant treatment with letrozole, are obliged for any reason to discontinue that drug. Our data suggest that they can safely switch to tamoxifen if required with little or no harm to their prognosis," he said.

Both drugs are used after initial treatment to prevent the cancer from returning. The medications work by preventing the production or activity of estrogen, which is associated with breast cancer recurrence in postmenopausal women. The drugs work differently, which may account for the benefit of letrozole over tamoxifen. Letrozole is from a class of drugs called aromatase inhibitors, which block the production of estrogen. Tamoxifen differs in that it interferes with the activity of estrogen, not the hormone's production.

Dr. Victor Vogel, national vice president of research at the American Cancer Society, believes that because letrozole is more effective and has fewer side effects than tamoxifen, it should be used for most patients.

"The message to lay people is letrozole is better. That's the unequivocal, unconfused message," Vogel said. "If you are a postmenopausal women taking tamoxifen for early breast cancer, it's probably a good idea to switch from tamoxifen to letrozole."

However, tamoxifen should be used for patients who find it difficult to take letrozole, Vogel said. "Somewhere between 15 and 25 percent of patients get significant muscle aches and joint aches with aromatase inhibitors. For those patients, tamoxifen is still a reasonable thing to do."

Dr. Larry Norton, deputy physician-in-chief of Breast Cancer Programs at Memorial Sloan-Kettering Cancer Center in New York City, said the study shows no advantage in starting women on tamoxifen and then switching them to letrozole.

"For postmenopausal people, it becomes clearer and clearer that the treatment of choice is an aromatase inhibitor without the use of tamoxifen," Norton said. "The window of opportunity for tamoxifen is narrowed by this paper."

"For most patients who are postmenopausal, I use an aromatase inhibitor exclusively," Norton added. "But I have used tamoxifen in postmenopausal patients for specific situations, such as extremity fragile bones, or such as intolerance of the aromatase inhibitor."

More information

There's more on breast cancer at the American Cancer Society.



SOURCES: Alan Coates, M.D., co-chair, scientific committee, International Breast Cancer Study Group, and clinical professor, School of Public Health, University of Sydney, Australia; Larry Norton, M.D., deputy physician-in-chief, Breast Cancer Programs, Memorial Sloan-Kettering Cancer Center, New York City; Victor Vogel, M.D., M.H.S., national vice president, research, American Cancer Society; Aug. 20, 2009, New England Journal of Medicine


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. The Other Cruciate Ligament: Newer Treatments for PCL Tears
2. Newer Blood Tests May Not Improve Heart Risk Assessment
3. FDA Panel OKs Newer Antipsychotics for Children
4. FDA Panel Mulls Newer Antipsychotics for Kids
5. Newer Antipsychotics May Boost Weight in Alzheimers Patients
6. Newer Sedative May Reduce Delirium in ICU Patients
7. Zoloft, Lexapro the Best of Newer Antidepressants
8. Newer Contraceptives Dont Increase Heart Risk
9. Newer Antipsychotics Pose Cardiac Risk: Study
10. Most Newer Antipsychotics No Better Than Older Ones, Just Different
11. Newer antipsychotics no better than older drug in treating child and adolescent schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Drug Beats Tamoxifen for Older Breast Cancer Patients
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... N.C. , June 24, 2016  Consumers ... decisions and regulators/payers have placed more emphasis on ... environment, patient support programs in the pharmaceutical industry ... patients, medications. Consequently, pharmaceutical companies are focusing on ... they are providing products and services that improve ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
Breaking Medicine Technology: